tolbutamide has been researched along with Diabetes Mellitus, Type 2 in 106 studies
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In advanced beta-cell failure, counterregulatory glucagon responses may be impaired due to a reduced decrement in insulin secretion during the development of hypoglycemia." | 7.73 | Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes. ( Bokhari, S; Cryer, PE; Gerich, JE; Gosmanov, NR; Israelian, Z; Meyer, C; Schorr, M; Szoke, E, 2005) |
| " Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12)." | 5.09 | Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000) |
| "We conducted a randomized placebo-controlled study to determine the effects of the thiazolidinedione compound troglitazone on whole-body insulin sensitivity (SI), pancreatic beta-cell function, and glucose tolerance in 42 Latino women with impaired glucose tolerance (IGT) and a history of gestational diabetes mellitus (GDM), characteristics that carry an 80% risk of developing NIDDM within 5 years." | 5.08 | Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. ( Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A, 1996) |
| " Plasma glucose and serum insulin, C-peptide, and proinsulin levels were measured before as well as 1 and 2 h after breakfast in 23 patients with non-insulin-dependent diabetes mellitus and 17 patients with impaired glucose tolerance." | 5.08 | Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. ( Awata, T; Inoue, I; Katayama, S; Negishi, K; Noji, S; Takahashi, K, 1997) |
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| "In advanced beta-cell failure, counterregulatory glucagon responses may be impaired due to a reduced decrement in insulin secretion during the development of hypoglycemia." | 3.73 | Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes. ( Bokhari, S; Cryer, PE; Gerich, JE; Gosmanov, NR; Israelian, Z; Meyer, C; Schorr, M; Szoke, E, 2005) |
| "The prevalence of pre-eclampsia was significantly increased in the group of women treated with metformin compared to women treated with sulphonylurea or insulin (32 vs." | 3.70 | Oral hypoglycaemic agents in 118 diabetic pregnancies. ( Damm, P; Hellmuth, E; Mølsted-Pedersen, L, 2000) |
| "Insulin tolerance test was done to assess the insulin sensitivity in a group of untreated non insulin dependent diabetic subjects before and after sulfonylurea (tolbutamide, glibenclamide, glipizide) therapy." | 3.68 | Effect of sulphonylurea therapy on insulin sensitivity in non insulin dependent diabetics. ( Dash, RJ; Khandekar, S; Sethi, BK, 1990) |
| "Of 386 NIDDM patients, 17 had the combined genotype exon 18 C/T and intron -3c/-3t (0." | 2.69 | Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. ( Aguilar-Bryan, L; Almind, K; Bryan, J; Clausen, JO; Echwald, SM; Ferrer, J; Hansen, L; Hansen, T; Inoue, H; Møller, AM; Pedersen, O; Permutt, MA; Urhammer, SA, 1998) |
| "Tolbutamide was associated with increases in body weight and postprandial insulin levels when taken alone, but these were ameliorated when tolbutamide was taken in combination with acarbose." | 2.68 | Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. ( Bray, GA; Coniff, RF; Seaton, TB; Shapiro, JA, 1995) |
| "Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily." | 2.67 | Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. ( Kruseman, AC; Menheere, PP; Müller, PG; Nijst, L; Sels, JP; Wolffenbuttel, BH, 1993) |
| " The dosage was adjusted to obtain adequate control or up to the maximum recommended dosage." | 2.67 | Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. ( Harrower, AD, 1991) |
| "In 13 non-obese patients with Type 2 diabetes mellitus who failed to achieve adequate blood glucose control on dietary treatment (fasting blood glucose 13." | 2.66 | A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy. ( van Koetsveld, PM; Verschoor, L; Weber, RF; Weeks, L; Wolffenbuttel, BH, 1989) |
| "20 patients with non insulin dependent diabetes mellitus (NIDDM), and within 20% of their ideal body weight were studied." | 2.66 | A comparative study of sulphonylurea and insulin therapy in non insulin dependent diabetics who had failed on diet therapy alone. ( Burden, AC; Kinghorn, HA; Samanta, A, 1987) |
| " The absorption rate of glibenclamide and tolbutamide was not affected by food." | 2.41 | [Timing of administration of sulfonyl urea derivatives]. ( de Smet, PA; Fischer, HR, 2000) |
| "No reduction of NIDDM development was seen." | 2.40 | Pharmacological intervention: the antidiabetic approach. ( Melander, A, 1998) |
| "The search for the genetic basis of NIDDM has magnified the need for an efficient representation of the pre-NIDDM phenotype." | 2.39 | Toward an integrated phenotype in pre-NIDDM. ( Ader, M; Bergman, RN; Rebrin, K; Steil, G; Watanabe, R, 1996) |
| "Compared to healthy subjects, our MODY3 individuals did not show any increased serum insulin response to tolbutamide, suggesting that HNF-1alpha mutation carriers are not characterized by sulphonylurea hypersensitivity." | 1.33 | Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers. ( Hansen, T; Hattersley, AT; Johansen, A; Njølstad, PR; Pearson, ER; Pedersen, O; Sagen, JV; Spyer, G; Søvik, O, 2005) |
| "Congenic strains for the two subloci (Niddm1f and Niddm1i) have been generated by transfer of GK alleles onto the genome of F344 rats." | 1.31 | Phenotyping of individual pancreatic islets locates genetic defects in stimulus secretion coupling to Niddm1i within the major diabetes locus in GK rats. ( Bergsten, P; Fakhrai-Rad, H; Galli, J; Lin, JM; Luthman, H; Ortsäter, H, 2001) |
| "Tolbutamide was the drug of choice; glibenclamide was introduced if glycemic control was not obtained after 2 to 3 months of tolbutamide therapy." | 1.30 | Treatment of NIDDM in youth. ( Kitagawa, T; Nitadori, Y; Owada, M, 1998) |
| "In conclusion, this novel NIDDM syndrome with reduced pancreatic insulin stores, which is similar to human NIDDM in that it has a significant response to glucose (although abnormal in kinetics) and preserved sensitivity to tolbutamide, may provide a particularly advantageous tool for pharmacological investigations of new insulinotropic agents." | 1.30 | Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. ( Broca, C; Gross, R; Hillaire-Buys, D; Manteghetti, M; Masiello, P; Novelli, M; Ribes, G; Roye, M, 1998) |
| "Type 2 diabetes mellitus (NIDDM) is a complex disorder encompassing multiple metabolic defects." | 1.30 | Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. ( Bergman, RN; Boehnke, M; Collins, FS; Ehnholm, C; Eriksson, J; Ghosh, S; Hauser, ER; Kohtamäki, K; Tuomilehto, J; Valle, T; Watanabe, RM, 1999) |
| "A subsequent study of 301 patients with NIDDM and 151 healthy control subjects revealed no additional mutations at codons 148, 497, or 844." | 1.29 | Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity. ( Bjørbaek, C; Clausen, JO; Echwald, SM; Granner, DK; Hansen, T; Pedersen, O; Printz, RL; Vestergaard, H; Zierath, JR, 1995) |
| "In the RW pedigree, MODY is associated with polymorphic DNA markers on chromosome 20q." | 1.29 | Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. ( Bell, GI; Fajans, SS; Halter, JB; Herman, WH; Ortiz, FJ; Polonsky, KS; Smith, MJ; Sturis, J, 1994) |
| "Therefore, the hyperproinsulinemia of type 2 diabetes and in insulinoma patients may be caused by additional defects in the proinsulin to insulin conversion process." | 1.28 | Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin. ( Creutzfeldt, W; Nauck, MA; Siegel, EG, 1991) |
| "Basal values of T increased in both T-IDDM and T-NIDDM, compared to IDDM and NIDDM, respectively." | 1.28 | Chronic effects of tolbutamide on myocardial tension during ischemia and reperfusion in perfused hearts isolated from insulin dependent and non insulin dependent diabetic rats. ( Mimura, G; Murakami, K; Oshiro, K; Sunagawa, R, 1991) |
| " The inter-relationship of tolbutamide dosage and concentration, and glucose and insulin concentrations were therefore examined in 54 out-patients (the observational group) and in 20 patients studied under controlled conditions (the experimental group)." | 1.28 | The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes. ( Alberti, KG; Antsiferov, ML; Ferner, RE; Kelman, AW; Rawlins, MD, 1991) |
| "No increase was noted in patients with Type 2 diabetes or with IGT." | 1.28 | Basal and tolbutamide-induced plasma somatostatin in healthy subjects and in patients with diabetes and impaired glucose tolerance. ( De Vroede, M; Michotte, Y; Segers, O; Somers, G, 1989) |
| "Glipizide has the most rapid absorption and onset of action, as well as the shortest half-life and effect-duration; hence the risk of long-lasting hypoglycemia is minute." | 1.27 | Clinical pharmacology of glipizide. ( Melander, A; Wåhlin-Boll, E, 1983) |
| "In these NIDDM patients, exposure of pancreatic beta-cells to sustained levels of sulfonylureas induces a reversible state of refractoriness to acute stimulation with sufonylureas but not to another secretagogue." | 1.27 | Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. ( Karam, JH; Nolte, MS; Salamon, E; Sanz, N, 1986) |
| " A short 12-week study was conducted which incorporated a cross-over design and the results were examined by variance analysis after dosage was individualized to the patient's requirements." | 1.24 | CLINICAL STUDIES OF TOLAZAMIDE AND TOLBUTAMIDE: COMPARATIVE EFFECTIVENESS OF CONTROL OF DIABETES MELLITUS. ( ANDERSON, DO; RENNIE, CS, 1963) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (23.58) | 18.7374 |
| 1990's | 47 (44.34) | 18.2507 |
| 2000's | 23 (21.70) | 29.6817 |
| 2010's | 9 (8.49) | 24.3611 |
| 2020's | 2 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 1 |
| Pagidipati, NJ | 1 |
| Califf, RM | 1 |
| McGuire, DK | 1 |
| Green, JB | 1 |
| Demets, D | 1 |
| George, JT | 1 |
| Gerstein, HC | 1 |
| Hobbs, T | 1 |
| Holman, RR | 1 |
| Lawson, FC | 1 |
| Leiter, LA | 1 |
| Pfeffer, MA | 1 |
| Reusch, J | 1 |
| Riesmeyer, JS | 1 |
| Roe, MT | 1 |
| Rosenberg, Y | 1 |
| Temple, R | 1 |
| Wiviott, S | 1 |
| McMurray, J | 1 |
| Granger, C | 1 |
| Misun, PM | 1 |
| Yesildag, B | 1 |
| Forschler, F | 1 |
| Neelakandhan, A | 1 |
| Rousset, N | 1 |
| Biernath, A | 1 |
| Hierlemann, A | 1 |
| Frey, O | 1 |
| Douros, A | 1 |
| Yin, H | 1 |
| Yu, OHY | 1 |
| Filion, KB | 1 |
| Azoulay, L | 1 |
| Suissa, S | 1 |
| Gravel, S | 1 |
| Chiasson, JL | 1 |
| Turgeon, J | 1 |
| Grangeon, A | 1 |
| Michaud, V | 1 |
| Bo, S | 1 |
| Castiglione, A | 1 |
| Ghigo, E | 1 |
| Gentile, L | 1 |
| Durazzo, M | 1 |
| Cavallo-Perin, P | 1 |
| Ciccone, G | 1 |
| Zhang, Q | 1 |
| Ramracheya, R | 1 |
| Lahmann, C | 1 |
| Tarasov, A | 1 |
| Bengtsson, M | 1 |
| Braha, O | 1 |
| Braun, M | 2 |
| Brereton, M | 1 |
| Collins, S | 1 |
| Galvanovskis, J | 1 |
| Gonzalez, A | 1 |
| Groschner, LN | 1 |
| Rorsman, NJ | 1 |
| Salehi, A | 1 |
| Travers, ME | 1 |
| Walker, JN | 1 |
| Gloyn, AL | 1 |
| Gribble, F | 1 |
| Johnson, PR | 1 |
| Reimann, F | 1 |
| Ashcroft, FM | 4 |
| Rorsman, P | 2 |
| Gjesing, AP | 1 |
| Hornbak, M | 1 |
| Allin, KH | 1 |
| Ekstrøm, CT | 1 |
| Urhammer, SA | 4 |
| Eiberg, H | 2 |
| Pedersen, O | 7 |
| Hansen, T | 7 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Liu, R | 1 |
| Wang, H | 1 |
| Xu, B | 1 |
| Chen, W | 1 |
| Turlova, E | 1 |
| Dong, N | 1 |
| Sun, CL | 1 |
| Lu, Y | 1 |
| Fu, H | 1 |
| Shi, R | 1 |
| Barszczyk, A | 1 |
| Yang, D | 1 |
| Jin, T | 1 |
| Mannucci, E | 1 |
| Feng, ZP | 1 |
| Sun, HS | 1 |
| Tsukada, S | 1 |
| Kobayashi, MA | 1 |
| Omori, S | 1 |
| Unoki, H | 1 |
| Maeda, S | 1 |
| Matsui, K | 1 |
| Oda, T | 1 |
| Nishizawa, E | 1 |
| Sano, R | 1 |
| Yamamoto, H | 1 |
| Fukuda, S | 1 |
| Sasase, T | 1 |
| Miyajima, K | 1 |
| Ueda, N | 1 |
| Ishii, Y | 1 |
| Ohta, T | 2 |
| Matsushita, M | 1 |
| Brown, SH | 1 |
| Abdelhafiz, AH | 1 |
| Abdelmoneim, AS | 1 |
| Hasenbank, SE | 1 |
| Seubert, JM | 1 |
| Brocks, DR | 1 |
| Light, PE | 2 |
| Simpson, SH | 1 |
| Lang, VY | 1 |
| Fatehi, M | 1 |
| Blume, JD | 1 |
| VOLK, BW | 2 |
| LAZARUS, SS | 2 |
| RENNIE, CS | 1 |
| ANDERSON, DO | 1 |
| Meier, JJ | 1 |
| Gallwitz, B | 1 |
| Schmidt, WE | 1 |
| Mügge, A | 1 |
| Nauck, MA | 2 |
| van de Laar, FA | 1 |
| Lucassen, PL | 1 |
| Kemp, J | 1 |
| van de Lisdonk, EH | 1 |
| van Weel, C | 1 |
| Rutten, GE | 1 |
| Schwartz, TB | 1 |
| Meinert, CL | 1 |
| Toye, AA | 1 |
| Lippiat, JD | 1 |
| Proks, P | 1 |
| Shimomura, K | 1 |
| Bentley, L | 1 |
| Hugill, A | 1 |
| Mijat, V | 1 |
| Goldsworthy, M | 1 |
| Moir, L | 1 |
| Haynes, A | 1 |
| Quarterman, J | 1 |
| Freeman, HC | 1 |
| Cox, RD | 1 |
| Sagen, JV | 1 |
| Pearson, ER | 1 |
| Johansen, A | 1 |
| Spyer, G | 1 |
| Søvik, O | 1 |
| Njølstad, PR | 1 |
| Hattersley, AT | 1 |
| Iwase, M | 1 |
| Nakamura, U | 1 |
| Uchizono, Y | 1 |
| Nohara, S | 1 |
| Sasaki, N | 1 |
| Sonoki, K | 1 |
| Iida, M | 1 |
| Ishiyama, N | 1 |
| Ravier, MA | 1 |
| Henquin, JC | 1 |
| Israelian, Z | 1 |
| Gosmanov, NR | 1 |
| Szoke, E | 1 |
| Schorr, M | 1 |
| Bokhari, S | 1 |
| Cryer, PE | 1 |
| Gerich, JE | 1 |
| Meyer, C | 1 |
| Chen, CC | 1 |
| Liu, IM | 2 |
| Cheng, JT | 2 |
| Becker, ML | 1 |
| Visser, LE | 1 |
| Trienekens, PH | 1 |
| Hofman, A | 1 |
| van Schaik, RH | 1 |
| Stricker, BH | 1 |
| Holländer, E | 2 |
| Melander, A | 3 |
| Wåhlin-Boll, E | 1 |
| Tattersall, RB | 1 |
| Appel, S | 1 |
| Rüfenacht, T | 1 |
| Kalafsky, G | 1 |
| Tetzloff, W | 1 |
| Kallay, Z | 1 |
| Hitzenberger, G | 1 |
| Kutz, K | 1 |
| Coniff, RF | 1 |
| Shapiro, JA | 1 |
| Seaton, TB | 1 |
| Bray, GA | 1 |
| Jarrett, RJ | 1 |
| Kindmark, H | 1 |
| Köhler, M | 2 |
| Arkhammar, P | 1 |
| Efendic, S | 1 |
| Larsson, O | 1 |
| Linder, S | 1 |
| Nilsson, T | 1 |
| Berggren, PO | 2 |
| Echwald, SM | 5 |
| Bjørbaek, C | 1 |
| Clausen, JO | 3 |
| Vestergaard, H | 1 |
| Zierath, JR | 1 |
| Printz, RL | 1 |
| Granner, DK | 1 |
| Streckfus, CF | 1 |
| Marcus, S | 1 |
| Welsh, S | 1 |
| Brown, RS | 1 |
| Cherry-Peppers, G | 1 |
| Brown, RH | 1 |
| Wolffenbuttel, BH | 2 |
| Nijst, L | 1 |
| Sels, JP | 1 |
| Menheere, PP | 1 |
| Müller, PG | 1 |
| Kruseman, AC | 1 |
| Herman, WH | 1 |
| Fajans, SS | 2 |
| Ortiz, FJ | 1 |
| Smith, MJ | 1 |
| Sturis, J | 1 |
| Bell, GI | 2 |
| Polonsky, KS | 1 |
| Halter, JB | 1 |
| Williams, BA | 1 |
| Smith, PA | 1 |
| Leow, K | 1 |
| Shimizu, S | 1 |
| Gray, DW | 1 |
| Brown, MB | 1 |
| Kaku, K | 1 |
| Inoue, Y | 1 |
| Kaneko, T | 1 |
| Hara, T | 1 |
| Nakamura, J | 1 |
| Koh, N | 1 |
| Sakakibara, F | 1 |
| Takeuchi, N | 1 |
| Hotta, N | 1 |
| Smits, P | 1 |
| Bijlstra, PJ | 1 |
| Russel, FG | 1 |
| Lutterman, JA | 1 |
| Thien, T | 1 |
| Berkowitz, K | 2 |
| Peters, R | 1 |
| Kjos, SL | 2 |
| Goico, J | 2 |
| Marroquin, A | 2 |
| Dunn, ME | 1 |
| Xiang, A | 1 |
| Azen, S | 1 |
| Buchanan, TA | 2 |
| Bergman, RN | 2 |
| Watanabe, R | 1 |
| Rebrin, K | 1 |
| Ader, M | 1 |
| Steil, G | 1 |
| Howes, LG | 1 |
| Sundaresan, P | 1 |
| Lykos, D | 1 |
| Hansen, L | 4 |
| Rouard, M | 1 |
| Vaxillaire, M | 1 |
| Møller, AM | 2 |
| Rasmussen, SK | 1 |
| Fridberg, M | 1 |
| Holst, JJ | 1 |
| Almind, K | 2 |
| Inoue, I | 1 |
| Takahashi, K | 1 |
| Noji, S | 1 |
| Awata, T | 1 |
| Negishi, K | 1 |
| Katayama, S | 1 |
| O'Brien, RC | 1 |
| Luo, M | 1 |
| Owada, M | 1 |
| Nitadori, Y | 1 |
| Kitagawa, T | 1 |
| Masiello, P | 1 |
| Broca, C | 1 |
| Gross, R | 1 |
| Roye, M | 1 |
| Manteghetti, M | 1 |
| Hillaire-Buys, D | 1 |
| Novelli, M | 1 |
| Ribes, G | 1 |
| Inoue, H | 1 |
| Ferrer, J | 2 |
| Bryan, J | 1 |
| Aguilar-Bryan, L | 1 |
| Permutt, MA | 1 |
| Levy, J | 1 |
| Atkinson, AB | 1 |
| Bell, PM | 1 |
| McCance, DR | 1 |
| Hadden, DR | 1 |
| Luo, J | 1 |
| Quan, J | 1 |
| Tsai, J | 1 |
| Hobensack, CK | 1 |
| Sullivan, C | 1 |
| Hector, R | 1 |
| Reaven, GM | 1 |
| Sakura, H | 1 |
| Ashcroft, SJ | 1 |
| Terauchi, Y | 1 |
| Kadowaki, T | 1 |
| Harvey, J | 1 |
| Ashford, ML | 1 |
| Cherrington, AD | 1 |
| Edgerton, D | 1 |
| Sindelar, DK | 1 |
| Lopez-Liuchi, JV | 1 |
| Meier, CA | 1 |
| Chang, SL | 1 |
| Lin, JG | 1 |
| Chi, TC | 1 |
| Lewis, GF | 1 |
| Carpentier, A | 1 |
| Vranic, M | 1 |
| Giacca, A | 1 |
| Barg, S | 1 |
| Renström, E | 1 |
| Bertorello, A | 1 |
| Bokvist, K | 1 |
| Eliasson, L | 1 |
| Holmes, WE | 1 |
| Thévenod, F | 1 |
| Furukawa, N | 1 |
| Komuro, G | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Watanabe, RM | 1 |
| Valle, T | 1 |
| Hauser, ER | 1 |
| Ghosh, S | 1 |
| Eriksson, J | 1 |
| Kohtamäki, K | 1 |
| Ehnholm, C | 1 |
| Tuomilehto, J | 1 |
| Collins, FS | 1 |
| Boehnke, M | 1 |
| Viviani, GL | 1 |
| Pacini, G | 1 |
| Feinglos, MN | 1 |
| Bethel, MA | 1 |
| Agardh, CD | 1 |
| Björgell, P | 1 |
| Nilsson-Ehle, P | 1 |
| de Smet, PA | 1 |
| Fischer, HR | 1 |
| Xiang, AH | 1 |
| Peters, RK | 1 |
| Ochoa, C | 1 |
| Azen, SP | 1 |
| Hellmuth, E | 1 |
| Damm, P | 1 |
| Mølsted-Pedersen, L | 1 |
| Paroni, R | 1 |
| Comuzzi, B | 1 |
| Arcelloni, C | 1 |
| Brocco, S | 1 |
| de Kreutzenberg, S | 1 |
| Tiengo, A | 1 |
| Ciucci, A | 1 |
| Beck-Peccoz, P | 1 |
| Genovese, S | 1 |
| Miura, T | 1 |
| Ichiki, H | 1 |
| Iwamoto, N | 1 |
| Kato, M | 1 |
| Kubo, M | 1 |
| Sasaki, H | 1 |
| Okada, M | 1 |
| Ishida, T | 1 |
| Seino, Y | 1 |
| Tanigawa, K | 1 |
| Ambye, L | 1 |
| Grarup, N | 1 |
| Kjems, LL | 1 |
| Vølund, A | 1 |
| Madsbad, S | 1 |
| Lin, JM | 1 |
| Ortsäter, H | 1 |
| Fakhrai-Rad, H | 1 |
| Galli, J | 1 |
| Luthman, H | 1 |
| Bergsten, P | 1 |
| AvRuskin, TW | 1 |
| Juan, CS | 1 |
| Katsumata, K | 1 |
| Katsumata, Y | 1 |
| Siegel, EG | 1 |
| Creutzfeldt, W | 1 |
| Harrower, AD | 1 |
| Kamińska-Galwas, B | 1 |
| Sroczyński, J | 1 |
| Oshiro, K | 1 |
| Murakami, K | 1 |
| Sunagawa, R | 1 |
| Mimura, G | 1 |
| Ferner, RE | 2 |
| Antsiferov, ML | 1 |
| Kelman, AW | 1 |
| Alberti, KG | 2 |
| Rawlins, MD | 2 |
| Khandekar, S | 1 |
| Sethi, BK | 1 |
| Dash, RJ | 1 |
| Josephkutty, S | 1 |
| Potter, JM | 1 |
| Gram, J | 1 |
| Kold, A | 1 |
| Jespersen, J | 1 |
| Czyzyk, A | 1 |
| Lao, B | 1 |
| Orłowska, K | 1 |
| Szczepanik, Z | 1 |
| Bartosiewicz, W | 1 |
| Weber, RF | 1 |
| van Koetsveld, PM | 1 |
| Weeks, L | 1 |
| Verschoor, L | 1 |
| Segers, O | 1 |
| De Vroede, M | 1 |
| Michotte, Y | 1 |
| Somers, G | 1 |
| Koev, D | 1 |
| Borisova, AM | 1 |
| Zlatareva, N | 1 |
| Kirilov, G | 1 |
| Mokuda, O | 1 |
| Murakami, I | 1 |
| Ikeda, T | 1 |
| Tominaga, M | 1 |
| Mashiba, H | 1 |
| Takeda, N | 1 |
| Yasuda, K | 1 |
| Horiya, T | 1 |
| Goto, S | 1 |
| Hayashi, M | 1 |
| Ito, Y | 1 |
| Aoyama, K | 1 |
| Miura, K | 1 |
| Samanta, A | 1 |
| Burden, AC | 1 |
| Kinghorn, HA | 1 |
| Borst, GC | 1 |
| Karam, JH | 1 |
| Sanz, N | 1 |
| Salamon, E | 1 |
| Nolte, MS | 1 |
| Qian, ZR | 1 |
| Zhong, XL | 1 |
| Fang, YA | 1 |
| Emanuele, NV | 1 |
| Lawrence, AM | 1 |
| Tatoń, J | 1 |
| Koliński, P | 1 |
| Horoszek-Maziarz, S | 1 |
| Berliński, E | 1 |
| Jaromczyk-Slisz, J | 1 |
| Rachoń, K | 1 |
| Wójcikowski, C | 1 |
| Słomiński, M | 1 |
| Orłowska-Kunikowska, E | 1 |
| Krupa-Wojciechowska, B | 1 |
| Kilo, C | 1 |
| Williamson, JR | 1 |
| Giugliano, D | 1 |
| Ceriello, A | 1 |
| Saccomanno, F | 1 |
| Quatraro, A | 1 |
| Paolisso, G | 1 |
| D'Onofrio, F | 1 |
| Ikegami, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Type 2 Diabetes on CYP450s Activities; Intersubject Variability in Drug Metabolism.[NCT02291666] | Phase 4 | 73 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes[NCT05616273] | 75 participants (Anticipated) | Observational | 2023-03-23 | Recruiting | |||
| Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)[NCT02838693] | 2,300 participants (Anticipated) | Observational | 2016-03-31 | Recruiting | |||
| Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure[NCT04841096] | Phase 3 | 172 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | ||
| Study of Improving Insulin Sensitivity by Combined Both Electroacupuncture and Drug Therapy[NCT00379379] | 26 participants | Interventional | 2005-01-31 | Completed | |||
| Effect of Gain on Closed-Loop Insulin[NCT02065895] | 8 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Glucose Area Under the Curve (AUC) Breakfast defines the total exposure to glucose during breakfast. Breakfast is typically considered the most difficult meal to control; low AUC is desirable.This outcome measure was analyzed for each of the three calibration error values (high error, no error and low error). (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 2:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l/min (Mean) |
|---|---|
| HIGH Error | 66.8 |
| NO Error | 48.8 |
| LOW Error | 37.4 |
Night-time in target range 5.0-8.33, following the 3 hour controller initialization period blood glucose remained at or near target. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 12:00 AM to 6:00 AM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | percentage of time in target range (Median) |
|---|---|
| HIGH Error | 88 |
| NO Errror | 100 |
| LOW Error | 80 |
Highest and lowest glucose concentrations obtained during breakfast meal. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 12:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Peak glucose concentration | Nadir glucose concentration | |
| Gain Decreased and Target Increased | 11.3 | 6.6 |
| Gain Increased and Target Decreased | 13.3 | 4.5 |
| Nadir Mean | 11.8 | 4.8 |
15 reviews available for tolbutamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Causality; Comorbidity; Diabetes Complications; | 2009 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe | 2012 |
Likelihood methods for measuring statistical evidence.
Topics: Biometry; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypog | 2002 |
Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
Topics: Animals; Cardiovascular Agents; Catheterization; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Age | 2004 |
[25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
Topics: Aged; Aging; Blood Glucose; Cardiovascular Diseases; Chlorpropamide; Diabetes Complications; Diabete | 1984 |
Extrapancreatic effects of sulfonylurea drugs.
Topics: Animals; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycolysis; Humans; Hypoglycemic Agents; Islets | 1995 |
Review of previous impaired glucose tolerance intervention studies.
Topics: Diabetes Mellitus, Type 2; Dietary Carbohydrates; Exercise; Follow-Up Studies; Glucose Intolerance; | 1996 |
Cardiovascular effects of sulphonylurea derivatives.
Topics: Adenosine Triphosphate; Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Glyburide; Humans | 1996 |
Toward an integrated phenotype in pre-NIDDM.
Topics: Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucose; Glucose Clamp Technique; Gluc | 1996 |
Cardiovascular effects of oral hypoglycaemic drugs.
Topics: Biguanides; Diabetes Mellitus, Type 2; Glyburide; Heart; Hemodynamics; Humans; Hypoglycemic Agents; | 1996 |
The direct and indirect effects of insulin on hepatic glucose production in vivo.
Topics: Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; H | 1998 |
Pharmacological intervention: the antidiabetic approach.
Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabeti | 1998 |
Therapy for type 2 diabetes: where do we stand after the UK prospective diabetes study?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diet Therapy; Dose-Res | 1999 |
[Timing of administration of sulfonyl urea derivatives].
Topics: Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administr | 2000 |
[Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets | 1985 |
16 trials available for tolbutamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial.
Topics: Acarbose; Diabetes Mellitus, Type 2; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Mid | 2004 |
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Anticholesteremic Agents; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; | 1995 |
Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Topics: Acarbose; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug | 1995 |
Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glybur | 1993 |
An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM.
Topics: Biomarkers; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Dietary Carbohydr | 1996 |
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LD | 1996 |
Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
Topics: Acarbose; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; | 1997 |
Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene.
Topics: Adolescent; Adult; Amino Acid Substitution; ATP-Binding Cassette Transporters; Diabetes Mellitus, Ty | 1998 |
Therapy of type 2 diabetes, cardiovascular death, and the UGDP.
Topics: Angioplasty, Balloon, Coronary; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 1999 |
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolera | 2000 |
Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM.
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Diet, Diabetic; Gliclazide; Glipizide; Gly | 1991 |
Comparison of tolbutamide and metformin in elderly diabetic patients.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Ty | 1990 |
A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy.
Topics: Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasti | 1989 |
A comparative study of sulphonylurea and insulin therapy in non insulin dependent diabetics who had failed on diet therapy alone.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Typ | 1987 |
[Clinical evaluation of a new sulfonylurea derivative, preparation SPC-703, based on a 5-year observation].
Topics: Chlorpropamide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Su | 1985 |
The controversial American University Group Diabetes Study--a look at sulfonylurea and biguanide therapy.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; H | 1985 |
75 other studies available for tolbutamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; | 2020 |
In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution.
Topics: Diabetes Mellitus, Type 2; Drug Discovery; Exenatide; Glucose; Humans; Hypoglycemic Agents; Insulin; | 2020 |
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus | 2017 |
Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Bupropion; Caffeine; Case-Control Studies; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cyto | 2019 |
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol | 2013 |
Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channels; Diabetes Mellitus, Type 2; Exocytosis; G | 2013 |
High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Family; Female; Genotype; Glucose; Glucose Tolerance Test; Humans; Insuli | 2014 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes.
Topics: Animals; Blotting, Western; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Typ | 2016 |
Transcription factor AP-2beta inhibits glucose-induced insulin secretion in cultured insulin-secreting cell-line.
Topics: Animals; Cell Line; Cricetinae; Diabetes Mellitus, Type 2; DNA Primers; Genetic Predisposition to Di | 2009 |
Pancreatic function of spontaneously diabetic torii rats in pre-diabetic stage.
Topics: Animals; Arginine; Benzoates; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibi | 2009 |
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Exp | 2012 |
Significance of effectiveness of combined insulin-orinase treatment in maturity-onset diabetes.
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Tolbutam | 1959 |
CLINICAL STUDIES OF TOLAZAMIDE AND TOLBUTAMIDE: COMPARATIVE EFFECTIVENESS OF CONTROL OF DIABETES MELLITUS.
Topics: Biomedical Research; Diabetes Mellitus, Type 2; Glycosuria; Humans; Hypoglycemic Agents; Tolazamide; | 1963 |
Physiological basis of the effectiveness of combined insulin-tolbutamide therapy in stable diabetes.
Topics: Diabetes Mellitus, Type 2; Insulin; Tolbutamide | 1959 |
The UGDP controversy: thirty-four years of contentious ambiguity laid to rest.
Topics: Cardiomyopathies; Clinical Trials as Topic; Diabetes Mellitus, Type 2; History, 20th Century; Humans | 2004 |
A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice.
Topics: Animals; Blood Glucose; Calcium Signaling; Crosses, Genetic; Diabetes Mellitus, Type 2; Fasting; Fem | 2005 |
Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Glucose Tolerance Tes | 2005 |
Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Topics: 3-O-Methylglucose; Administration, Oral; Anesthesia; Animals; Blood Glucose; Blood Pressure; Conscio | 2005 |
Dual mechanism of the potentiation by glucose of insulin secretion induced by arginine and tolbutamide in mouse islets.
Topics: Animals; Arginine; Calcium; Cytosol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe | 2006 |
Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose Clamp Technique; Humans; Hypoglycemia; H | 2005 |
Improvement of insulin resistance by miracle fruit (Synsepalum dulcificum) in fructose-rich chow-fed rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dose-Respo | 2006 |
Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type | 2008 |
[Testing insulin and sulfonylurea sensitivity in type II diabetes mellitus].
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; | 1984 |
Clinical pharmacology of glipizide.
Topics: Biological Availability; Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Glipizide; Glybur | 1983 |
History of diabetes: UGDP Study Group.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Multicenter Studies | 1995 |
Oscillations in cytoplasmic free calcium concentration in human pancreatic islets from subjects with normal and impaired glucose tolerance.
Topics: Aged; Aged, 80 and over; Calcium; Cytoplasm; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tol | 1994 |
Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity.
Topics: Adult; Alleles; Amino Acid Sequence; Anthropometry; Base Sequence; Blood Glucose; Body Mass Index; C | 1995 |
Parotid function and composition of parotid saliva among elderly edentulous African-American diabetics.
Topics: Aged; Analysis of Variance; Baltimore; Black People; Case-Control Studies; Diabetes Mellitus; Diabet | 1994 |
Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree.
Topics: Adolescent; Adult; Blood Glucose; Child; Chromosomes, Human, Pair 20; Diabetes Mellitus, Type 2; Fem | 1994 |
Two types of potassium channel regulated by ATP in pancreatic B cells isolated from a type-2 diabetic human.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adult; Diabetes Mellitus, Type 2; Electric Conductivi | 1993 |
Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young.
Topics: Adolescent; Adult; Age Factors; Blood Glucose; Child; Chlorpropamide; Chromosomes, Human, Pair 20; D | 1993 |
Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM.
Topics: Adenosine Triphosphate; Adult; Blood Glucose; C-Peptide; Cohort Studies; Denmark; Diabetes Mellitus, | 1997 |
Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Glucose T | 1997 |
The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro.
Topics: Administration, Oral; Adult; Antioxidants; Ascorbic Acid; Coronary Artery Disease; Diabetes Mellitus | 1997 |
Treatment of NIDDM in youth.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Japan; | 1998 |
Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide.
Topics: Animals; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Glucos | 1998 |
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; | 1998 |
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; | 1998 |
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; | 1998 |
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; | 1998 |
Nongenetic mouse models of non-insulin-dependent diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Di | 1998 |
Glucose modulation of ATP-sensitive K-currents in wild-type, homozygous and heterozygous glucokinase knock-out mice.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Diabetes Mellitus, Type 2; Eukaryotic Cells; Gluc | 1998 |
Insulin occludes leptin activation of ATP-sensitive K+ channels in rat CRI-G1 insulin secreting cells.
Topics: Adenosine Triphosphate; Androstadienes; Animals; Binding, Competitive; Chromones; Diabetes Mellitus, | 1998 |
An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats.
Topics: Acupuncture Points; Animals; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Experimental; Diabete | 1999 |
Resistance to insulin's acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes.
Topics: Adult; Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dogs; Fatty Acids, Nonesterifie | 1999 |
The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Antibodies, Monoclonal; ATP Binding Casse | 1999 |
JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Butyrates; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Tolerance Test; | 1999 |
Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus | 1999 |
Reduced glucose effectiveness as a feature of glucose intolerance: evidence in elderly type-2 diabetic subjects.
Topics: Adult; Age Factors; Aged; Aging; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Fem | 1999 |
The effects of tolbutamide on lipoproteins, lipoprotein lipase and hormone-sensitive lipase.
Topics: Adipocytes; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Activation; Fe | 1999 |
Oral hypoglycaemic agents in 118 diabetic pregnancies.
Topics: Abruptio Placentae; Adult; Birth Weight; Cesarean Section; Cohort Studies; Diabetes Mellitus, Type 2 | 2000 |
Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.
Topics: Adult; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Overdose; Electrophores | 2000 |
Antidiabetic activity of the rhizoma of Anemarrhena asphodeloides and active components, mangiferin and its glucoside.
Topics: Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glucos | 2001 |
Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus.
Topics: Adult; Aged; Alleles; ATP-Binding Cassette Transporters; Blood Glucose; C-Peptide; Diabetes Mellitus | 2001 |
Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; | 2001 |
Phenotyping of individual pancreatic islets locates genetic defects in stimulus secretion coupling to Niddm1i within the major diabetes locus in GK rats.
Topics: Alleles; Animals; Crosses, Genetic; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Gl | 2001 |
Transient neonatal diabetes mellitus, type 4, type 1 diabetes mellitus, or MODY: which disease is it, anyway?
Topics: Adult; Arginine; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2002 |
Adverse effect on diabetes control of concomitant glibenclamide and tolbutamide.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Glyburide; Humans; Male; Mi | 1991 |
Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Insulin; Insul | 1991 |
[Evaluation of hepatic microsomal enzyme activity using C-l4-labeled aminopyrine breath test in patients with diabetes mellitus type 2 treated with tolbutamide].
Topics: Adult; Aged; Aminopyrine; Breath Tests; Carbon Radioisotopes; Cytochrome P-450 Enzyme System; Diabet | 1991 |
Chronic effects of tolbutamide on myocardial tension during ischemia and reperfusion in perfused hearts isolated from insulin dependent and non insulin dependent diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1991 |
The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 1991 |
Effect of sulphonylurea therapy on insulin sensitivity in non insulin dependent diabetics.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glipizide; Glyburide; Humans; Insulin Resistance; Middle A | 1990 |
Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide).
Topics: Aged; Diabetes Mellitus, Type 2; Fibrinolysis; Gliclazide; Humans; Middle Aged; Sulfonylurea Compoun | 1989 |
[Effect of antidiabetics on post-exercise alaninemia in patients with non-insulin-dependent diabetes mellitus (type 2)].
Topics: Adult; Alanine; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Exercise; E | 1989 |
Basal and tolbutamide-induced plasma somatostatin in healthy subjects and in patients with diabetes and impaired glucose tolerance.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucose To | 1989 |
[Combination treatment with insulin and sulfonylurea. Results of a 5-year study].
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies | 1989 |
[Effect of antihypertensive drugs on insulin secretion and efficacy].
Topics: Adult; Aged; Antihypertensive Agents; C-Peptide; Diabetes Mellitus, Type 2; Drug Evaluation; Drug In | 1989 |
Impaired beta-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Female; Glucose; H | 1988 |
Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; | 1988 |
Glucose-to-insulin ratio in intravenous tolbutamide test predicts long-term therapeutic outcome in NIDDM.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Insulin; Prognosis; Tolbutamide | 1988 |
Recurrent sulfonylurea induced nocturnal hypoglycemia managed with tolbutamide.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Male; Recurrence; | 1988 |
Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM.
Topics: Aged; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Is | 1986 |
[Traditional Chinese medicine combined with Western medicine in the treatment of diabetic peripheral neuropathy].
Topics: Acupuncture Therapy; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Neuropath | 1987 |
Management of type II diabetes mellitus. Achieving optimum metabolic control.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Glycated Hemoglobin; Humans; | 1985 |
Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.
Topics: Adult; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprostone; Drug Interactions; Glucose; | 1985 |
[The effect of aging on pharmacokinetics and pharmacodynamics of tolbutamide].
Topics: Administration, Oral; Adult; Aged; Aging; Diabetes Mellitus, Type 2; Humans; Kinetics; Male; Middle | 1985 |